An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
The VL-AdCre system enables effective removal of exogenous components following gene knockout, thus avoiding tumor immune rejection and enhancing the accuracy and reproducibility of in vivo cancer immunology research.
Authors
- Fei Li (ORCID: https://orcid.org/0000-0002-1973-6611)
- Tian Xu (ORCID: https://orcid.org/0009-0009-6489-7834)
- Shuaihu Li (ORCID: https://orcid.org/0000-0002-2049-7304)
- Yan Shang (ORCID: https://orcid.org/0009-0007-2631-6256)
- Yihua Sun (ORCID: https://orcid.org/0000-0002-5287-0601)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Pudong Medical Center (CN)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1158/0008-5472.can-25-0809
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.00